Our purpose, strategy and culture

Our mission

2'48''

View video on YouTube

Our strategy

We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Our portfolio

Vaccines

Specialty medicines

General medicines

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is helping protect people from meningitis, shingles, RSV, flu, polio and many more. Our portfolio of more than 20 marketed vaccines is one of the industry's broadest. We deliver over 1.5 million doses of our vaccibes every day; and 4 out of 10 infants born each year receive at least one GSK vaccine.

Belgium is home to the core of GSK's Vaccines division, with three major production sites in Wavre, Rixensart and Gembloux, as well as the international operations centre 'GSK Vaccines'. This represents the largest industrial network for vaccine production in the world.

Specialty products are prescribed by specialist healthcare practitioners. For GSK, these include products in the areas of infectious diseases and severe asthma. We offer life-changing cancer drugs. In addition, we offer medicines for immune diseases, including the first new medicine in 50 years for lupus, a chronic autoimmune disease from which more than 4000 Belgian patients suffer.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.

First-line medicines are generally prescribed by general practitioners. At GSK, these include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve the health and lives of millions of people around the world. Our portfolio of more than 150 primary care products is supplied 112 countries worldwide. GSK in Belgium, with its portfolio of respiratory treatments, remains the industry leader.

More on our portfolio and how we treat disease

Our therapeutic areas

Infectious diseases

There’s a huge need for innovation to tackle chronic infections, seasonal infections, common childhood diseases, rare but devastating conditions (meningitis) and a range of bacterial infections made more challenging by antimicrobial resistance (AMR); as well as diseases which predominately impact lower-income countries like malaria and TB.

Our infectious diseases portfolio is the broadest in the industry and, including HIV, accounts for two thirds of our pipeline.

HIV

Our goal is to minimise the impact of HIV on people’s lives through treatment, prevention and ultimately cure.

We are a world leader in next-generation HIV treatment and prevention, through ViiV Healthcare, the world’s only specialist HIV pharmaceutical company, which we majority own. We pioneered the first HIV treatments in the 1980s and we are leading the way in changing the landscape for people living with HIV today.

Oncology

We develop cancer medicines with life-changing potential for patients with ovarian cancer, endometrial cancer and multiple myeloma. We’ve accelerated this research and currently have three marketed therapies and a further nine assets in development.

Respiratory & Immunology

We’re unlocking the science of the immune system to develop medicines for immune-mediated conditions including lupus, eosinophilic-driven diseases such as severe eosinophilic asthma, COPD and other inflammatory diseases.

Our innovative medicines help millions of people with immune and respiratory conditions.

Our long-term priorities

We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. By harnessing our science and technology, we have an opportunity to prevent disease in the first place, as well as change the course of a disease – helping to prevent or slow progression of an illness and limit long-term complications. Our broad portfolio and pipeline continues to strengthen, with key milestones across our core therapeutic areas in 2023. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.

How we innovate

Facts and figures on R&D in Belgium

vaccine-candidates
19
euros investment in R&D in 2023
1.5 billion
scientific collaborations with Belgian universities and research centers
20

Facts and figures on R&D worldwide

major approvals in 2023
4
potential new vaccines and medicines in Phase 3 and registration
18
vaccines and medicines in our pipeline
71

We’re confident in our future. Our bold ambitions for patients are reflected in our upgraded growth outlooks to 2026 and 2031. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.

Facts and figures on performance in Belgium

of exported vaccines to > 160 countries in 2023
99%
with more than 10% of all exports from Wallonia in 2023
1st exporter

Facts and figures on performance worldwide

vaccines delivered in 2023
>767 million
packs of medicines and doses of vaccines delivered in 2023
2.3 billion

Being a responsible business means getting ahead of disease together in the right way. That’s why ESG is embedded in our strategy and supports our sustainable performance and long-term growth. We therefore need to consider ESG impacts across everything we do, from the lab to the patient. We have identified six ESG focus areas that address what is most material to our business and the issues that matter to our stakeholders. These focus areas are access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, product governance.

In Belgium, we are committed to sustainability with initiatives to maintain a healthy planet for healthy people. We’re committed to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045. We also want to be recognised for our inclusiveness, so we encourage and celebrate diversity. Respect and inclusion are an integral part of our corporate culture.

Our culture

Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.

Two female employees walking in a building